

BRIEF REPORT

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG

Bronwyn Bosch (1), Godspower Akpomemie (1), Nomathemba Chandiwana (1), Simiso Sokhela (1), Andrew Hill (2), Kaitlyn McCann (3), Ambar Qavi (3), Manya Mirchandani (3), Willem Daniel Francois Venter (1)

¹Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; ²Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom; ³Faculty of Medicine, Imperial College, London, UK

Participants randomised to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC+DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low density lipoprotein, triglycerides, glucose and glycated haemoglobin.

Corresponding author: Manya Mirchandani Imperial College London London U.K.
 manya.6269@gmail.com

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Keywords: tenofovir alafenamide, efavirenz, dolutegravir, body weight, HIV

INTRODUCTION

World Health Organization (WHO) guidelines for HIV treatment currently recommend tenofovir disoproxil fumarate (TDF) with either lamivudine (3TC) or emtricitabine (FTC) plus dolutegravir (DTG) as preferred first-line antiretroviral therapy (ART). DTG replaced efavirenz (EFV) in 2019 in first-line regimens due to potency, barrier to resistance, cost, and safety benefits over EFV [1].

Tenofovir alafenamide (TAF), a prodrug of tenofovir, is the recommended alternative to TDF for patients with renal impairment or established osteoporosis but endorsed more broadly in higher income countries [1]. WHO does not currently advocate a wholesale programmatic switch from TDF to TAF, due to associations with increased weight gain, worsened lipid profile, equivalent renal and bone toxicity and virological potency when compared to unboosted TDF, as well as concerns regarding drug interactions, unknown pregnancy outcomes, and high cost [2] [3].

In contrast, some studies have observed the mitigating effect of TDF and EFV on weight gain. EFV has been associated with significant side effects including neuropsychiatric side effects and increases in lipids and serum glucose levels [4]. Weight loss is higher for people with cytochrome polymorphisms resulting in slower metabolism of the drug, this then conferring other neurological and metabolic toxicities [5, 6]. TDF has been associated with a higher risk of weight loss in a recent analysis of HIV-negative people taking pre-exposure prophylaxis therapy [5, 6].

ADVANCE was an investigator-led randomized controlled trial evaluating the efficacy and safety of two newer antiretroviral combinations; TAF/FTC+DTG and TDF/FTC+DTG, as compared with TDF/FTC/EFV [7]. The trial recruited from routine HIV testing sites, based in Johannesburg, South Africa. ADVANCE demonstrated virological non-inferiority at 48, 96 and 192 weeks, with significant weight gain in the two DTG-containing arms, which was especially marked in the TAF/FTC+DTG arm. After week 192, participants were switched to open-label TDF/3TC/DTG as per the national guidelines, and evaluated here after further informed consent processes, following at least 52 weeks of follow up in the state ART programme. The aim of the study, CHARACTERISE, was to evaluate the change in clinical and metabolic parameters after this move to the standard-of-care ART regimen.

METHODS

Study setting

CHARACTERISE enrolled residents of inner-city Johannesburg from July-November 2022 who had previously been part of ADVANCE and were not pregnant at the time of screening.

Study design

CHARACTERISE evaluated outcomes after a minimum of 52 weeks of open label TDF/3TC/DTG. Results were evaluated for weight, lipids, fasting glucose, HbA1C, systolic/diastolic blood pressure and HIV RNA. Participants with elevations in HIV RNA were re-tested at least one month after adherence counselling. The methods of analysis followed the usual procedures for ADVANCE as described in the previous publications [8, 9]. Results for changes in weight and metabolic parameters are displayed as median and interquartile range (IQR). Changes within each treatment group were evaluated using the paired non-parametric Wilcoxon signed-rank test.

The trial was approved by the University of the Witwatersrand Human Research Ethics Committee and received local regulatory approval. All patients provided informed consent prior to any study procedures.

Role of funding source

Unitaid contributed to the study design of CHARACTERISE.

RESULTS

Out of 1053 patients who were randomised to ADVANCE, 172 participated in CHARACTERISE. Results from CHARACTERISE are available for 70 of the 351 participants originally in the TAF/FTC+DTG arm at the end of ADVANCE, 71 of the 351 participants in the TDF/FTC+DTG arm and 31 of the 351 participants in the TDF/FTC/EFV arm. Part of the reason for the low number in the TDF/FTC/EFV arm, was that the local clinics were still transitioning to TDF/3TC/DTG, with much residual stock, and it appeared the local nurses elected to continue EFV-based ART in many of these patients rather than switch to TDF/3TC/DTG. Overall, patients in CHARACTERISE were similar to those not enrolled, in terms of sex ($p=0.10$), CD4 ($p=0.18$) and HIV RNA ($p=0.93$). However, there were significant differences in their weight ($p=0.0023$). The mean weight of participants in CHARACTERISE was 79 kg and the mean weight of participants who did not enrol in CHARACTERISE was 74 kg.

In the CHARACTERISE study, baseline demographics were similar across the original randomised arms (Table 1). Participants were 62% female, 100% Black and 34% from outside of South Africa. Amongst the 34% who were from outside South Africa, 50 were from Zimbabwe,

2 from Malawi, 3 from Mozambique and 4 from other regions. The median baseline CD4 count was 570.5 cells/uL [IQR: 422, 795] with 98% having HIV RNA <50 copies/mL.

Weight

For women switching from TAF/FTC+DTG to TDF/3TC/DTG after week 192, there was a statistically significant reduction in weight (median: -1.6kg, p=0.0125). This change in weight was not significant in men (median: -0.2kg, p=0.2561). There was a statistically significant reduction in BMI for women (median: -0.57 kg/m², p=0.0106) but not men (median: -0.08, p=0.2473).

Participants switching from TDF/FTC/EFV to TDF/3TC/DTG, showed a significant increase in body weight (median: +2.9, p=0.02) and BMI (median: +1.01, p=0.0225). This change in weight was significant for the subset of men (median: +2.3, p=0.0464) but not women (median: +2.9, p=0.1127).

For participants in the TDF/FTC+DTG arm switching to TDF/3TC/DTG, there was no significant change in weight and BMI for either women or men.

Lipids, glucose, blood pressure and hba1c

Participants switching from TAF/FTC+DTG to TDF/3TC/DTG after week 192 showed significant reductions in total cholesterol (p=0.0018), LDL (p<0.001), triglycerides (p=0.0254), glucose (p=0.0003) and HbA1C (p=0.0004). The reduction in HDL and increase in systolic and diastolic blood pressure was not significant. Participants switching from TDF/FTC/EFV to TDF/3TC/DTG showed significant decreases in total cholesterol (p=0.0113), LDL (p=0.0012), HDL (p=0.0495), triglycerides (p=0.0575) and HbA1C (p=0.0082). The reduction in glucose and increase in systolic and diastolic blood pressure was not significant. For participants switching from TDF/FTC+DTG to TDF/3TC/DTG, there was a significant increase in total cholesterol (p=0.0009), HDL (p=0.0209) and systolic blood pressure (p=0.0206). However, changes in LDL, triglycerides, glucose, HbA1C and diastolic blood pressure were not significant.

HIV RNA

After at least 52-weeks on TDF/3TC/DTG, HIV RNA was undetectable in 68/68 (100%) participants originally in the TAF/FTC+DTG arm, 68/70 (97%) participants in the TDF/FTC+DTG arm and 25/28 (89%) in the TDF/FTC/EFV arm. There were eight elevations in HIV RNA. Of these, three participants re-suppressed after adherence counselling. However, one participant did not re-suppress and four did not return for their scheduled follow-up visit.

DISCUSSION

Millions of PLWH worldwide have switched from TDF/3TC/EFV or similar regimens, to TDF/3TC/DTG in the last five years. In the CHARACTERISE study, participants who switched from TDF/FTC/EFV to TDF/3TC/DTG gained a median 2.9kg. We also saw small improvements in LDL cholesterol, triglycerides, fasting glucose and HbA1C during the switches from TDF/FTC/EFV to TDF/3TC/DTG. Again, this change is expected, given the previously described metabolic effects of EFV [4].

Women who switched from TAF/FTC+DTG to TDF/3TC/DTG lost a median 1.6kg, and overall, this cohort had a slightly improved glucose and lipid profile. The results from CHARACTERISE are consistent with those seen in other observational studies from Finland and Germany in 292 and 385 participants, respectively [10, 11].

With weight gain persisting as a potentially major health complication with the use of all modern ART, risks for the development of long-term cardiac disorders remain of concern. A previously published analysis on the 5- and 10-year risks of cardiovascular disease (CVD) and diabetes was conducted on the same ADVANCE population at week 96 and demonstrated that participants on the TAF/FTC+DTG regimen had significantly greater risk scores for development of CVD or diabetes, driven by weight gain, in comparison to the TDF-containing groups [12]. A switch from TAF to TDF may be clinically justified in patients, especially women experiencing weight gain and those with glucose or lipid disorders, although it is unclear whether this weight loss will be maintained, or whether other weight loss measures will be required.

Limitations of the CHARACTERISE study include the open-label design and the relatively small sample size: only 16% of the original 1053 participants participated in the trial extension, so the statistical power to evaluate effects of switching in women and men is limited. There was low participation by men, reflective of attrition to HIV care of men in HIV programmes. There is potential for selection bias in those who chose to participate in CHARACTERISE versus those who did not. The trial was conducted in inner-city Johannesburg, with participants coming from across the region and recruited from routine patient care, factors which strengthen the generalisability of the study. This trial was also conducted in a region of highest global genetic diversity. However, this study should be repeated in Asian, Hispanic and Caucasian populations.

Current WHO recommendations for TDF/3TC/DTG as the preferred first-line regimen appear to be further substantiated by our study and are very reassuring for the participants switched from EFV-based regimens. Ultimately, countries such as Botswana that are moving away from TDF/3TC/DTG in favour of TAF/FTC+DTG, may want to consider preservation of TDF-

containing regimens as an option for patients with ongoing, significant weight gain and metabolic disease, sadly a significant proportion, of this population.

NOTES

Acknowledgements: We would like to thank Alexander Thomas for helping with the analysis.

Funders: Unitaid, U.S Agency for International Development (USAID), the South African Medical Research Council, and ViiV Health Care, with investigational products provided by ViiV Health Care and Gilead Sciences, with salary support to Dr Venter under the HLB-SIMPL Alliance sponsored by the National Heart, Lung and Blood Institute and funded under grant numbers UG3HL156388 with the U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute (NIH/NHLBI). The contents are solely the responsibility of the authors and do not necessarily represent the views any of the funders. The study received ethics approvals from the University of the Witwatersrand's Human Research Ethics Committee (2204410).

Grant number: 2016-07-Wits RHI

Potential Conflicts of Interest: Dr. Venter reports receiving lecture fees and travel support from Roche, grant support, advisory board fees, and provision of drugs from Gilead Sciences, advisory board fees from ViiV Healthcare, lecture fees from Merck and Adcock Ingram, and lecture fees and advisory board fees from Johnson & Johnson and Mylan. Dr. Venter also reports honoraria for educational talks and advisory board membership for Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi and Virology Education; participation on NIH International DSMB; unpaid roles as member of SAHCS prior board, Dira Sengwe board and WHO and local multiple guideline committees. Dr. Venter's unit receives funding from the Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, AIDS Fonds, Unitaid, Foundation for Innovative New Diagnostics and the Children's Investment Fund Foundation, has recently received funding from USAID, and receives drug donations from ViiV Healthcare, Merck, J&J and Gilead Sciences for investigator-led clinical studies. The unit does investigator-led studies with Merck and ViiV providing financial support and is doing commercial drug studies for Merck. The unit performs evaluations of diagnostic devices for multiple biotech companies. Importantly, the unit is doing research, investigator-led, with drug donations from ViiV and JJ, for treatment and PrEP, on LAIs. Dr. Hill reports UNITAID – WHO research grant, unrelated to this work. Dr. Bosch reports speaker honoraria at educational events from Johnson and Johnson and Cipla; support for attendance of HIV Glasgow 2022 from Johnson and Johnson; an unpaid role as Member of the South African Adult Third Line ART Committee. Dr. Akpomemie reports grants unrelated to this work from USAID; UNITAID, and South African Medical Research Council; and donation of investigational drug from ViiV Healthcare and Gilead Sciences. Dr. Chandiwana declares grants and non-financial support from Shin Poong Pharm. Co. Ltd., Merck, Johnson & Johnson grants, and Novo Nordisk outside the submitted work and paid to institution; honoraria from Cipla, Johnson & Johnson, and Novo Nordisk outside the submitted work and paid to author; unpaid participation as DSMB member of a study titled Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial; and a role as non-executive member of non-profit of the South Africa Breast Reserve. None of the other authors have any conflicts of interest to declare.

References

1. WHO. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Available at: <https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations>. Accessed 23 September 2022.
2. Surial B, Ledergerber B, Calmy A, et al. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. *J Infect Dis* **2020**; 222(4): 637-45.
3. Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14894 patients across 14 trials. *Aids* **2020**; 34(15): 2259-68.

4. Sinxadi PZ, McIlleron HM, Dave JA, et al. Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. *Medicine (Baltimore)* **2016**; 95(2): e2385.
5. Griesel R, Maartens G, Chirehwa M, et al. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. *Clin Infect Dis* **2021**; 73(11): e3902-e9.
6. Shah S, Pilkington V, Hill A. Is tenofovir disoproxil fumarate associated with weight loss? *Aids* **2021**; 35(Suppl 2): S189-s95.
7. Venter WDF, Bosch B, Sokhela S, et al. Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV - weight gain. PELBB01. *AIDS* 2022. Montreal, Canada, **2022**.
8. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *The Lancet HIV* **2020**; 7(10): e666-e76.
9. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. *New England Journal of Medicine* **2019**; 381(9): 803-15.
10. Kauppinen KJ, Aho I, Sutinen J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. *Aids* **2022**; 36(10): 1337-44.
11. Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. *Aids* **2019**; 33(15): 2387-91.
12. McCann K, Shah S, Hindley L, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. *Aids* **2021**; 35(10): 1657-65.

Table 1: Baseline characteristics and changes in weight and metabolic parameters from switch to TDF/3TC/DTG by original treatment received: CHARACTERISE trial

Group	TAF/FTC+DTG (n=70)	TDF/FTC+DTG (n=71)	TDF/FTC/EFV (n=31)
Baseline characteristics*			
Sex (% Female)	41/70 (59%)	41/71 (58%)	24/31 (77%)
Country (% South Africa)	42/70 (60%)	51/71 (72%)	20/31 (64%)
Weight (kg)	81.1 [71.5, 89.1]	72.9 [61.7, 86.3]	74.3 [61.8, 100.5]
BMI (kg/m ²)	28.0 [23.9, 31.8]	25.9 [22.5, 30.6]	25.6 [23.6, 33.1]
HIV RNA <50 copies/mL (%)	66/67 (98%)	62/64 (97%)	23/23 (100%)
CD4 count (cells/uL)	560 [424, 787]	549 [407.5, 743.5]	677 [544, 882]
Cholesterol (mmol/L)	3.9 [3.5, 4.8]	3.7 [3.2, 4.3]	4.5 [3.6, 4.91]
LDL (mmol/L)	2.6 [2.2, 3.1]	2.3 [1.9, 2.9]	2.8 [2.3, 3.27]
HDL (mmol/L)	1.1 [0.9, 1.3]	1.1 [0.9, 1.3]	1.3 [1.0, 1.6]
Triglycerides (mmol/L)	0.9 [0.7, 1.2]	0.8 [0.6, 1.0]	0.9 [0.7, 1.3]
Fasting glucose	4.9 [4.5, 5.2]	4.9 [4.6, 5.1]	4.7 [4.5, 5.1]

(mmol/L)			
HbA1c (mmol/L)	5.5 [5.1, 5.7]	5.5 [5.2, 5.7]	5.5 [5.2, 5.7]
Systolic blood pressure (mmHg)	127 [119, 134]	122 [117, 132]	118 [113, 126]
Diastolic blood pressure (mmHg)	83 [78, 88]	82 [77.5, 86]	76 [72, 83]
Changes from switch*			
Weight (kg)	-1.2 [-3.8, 1], p=0.0057	-0.1 [-2.1, 2.2] (n.s.)	+2.9 [-0.7, 4.9], p=0.02
BMI (kg/m ²)	-0.4 [-1.3, 0.3], p=0.0048	-0.05 [-0.7, 0.7] (n.s.)	+1.0 [-0.2, 1.9], p=0.0225
Total cholesterol (mmol/L)	-0.2 [-0.5, 0.1], p=0.0018	+0.2 [-0.1, 0.4], p=0.0009	-0.3 [-0.8, 0.01], p=0.0113
LDL cholesterol (mmol/L)	-0.3 [-0.6, -0.01], p=0.000	-0.01 [-0.2, 0.2] (n.s.)	-0.3 [-0.5, -0.1], p=0.0012
HDL (mmol/L)	-0.03 [-0.2, 0.1] (n.s.)	+0.04 [-0.1, 0.2], p=0.0209	-0.1 [-0.3, 0.05], p=0.0495
Triglycerides (mmol/L)	-0.1 [-0.3, 0.09], p=0.0254	-0.02 [-0.2, 0.2] (n.s.)	-0.1 [-0.3, 0.05], p=0.0575
Fasting glucose (mmol/L)	-0.2 [-0.5, 0.1], p=0.0003	0 [-0.3, 0.2] (n.s.)	-0.1 [-0.3, 0.1] (n.s.)
HbA1c (mmol/L)	-0.1 [-0.3, 0], p=0.0004	-0.1 [-0.3, 0.1] (n.s.)	-0.15 [-0.2, 0], p=0.0082
Systolic blood pressure (mmHg)	+1.5 [-6, 14] (n.s.)	+3 [-2.5, 10], p=0.0206	+6 [-10, 13] (n.s.)
Diastolic blood pressure (mmHg)	+2 [-4, 6] (n.s.)	+0.5 [-5.5, 4.5] (n.s.)	+2 [-4, 11] (n.s.)
HIV RNA<50 copies/mL at or after week 52 (%)	68/68 (100%)	68/70 (97%)	25/28 (89%)

*Note:

Continuous variables are displayed as Median and interquartile range (IQR). Count variables are displayed as n/N and
n.s. = not significant